Nuvalent, Inc. (NUVL)

66,53 -2,11 (-3,07%) In data: 03:00PM EDT. Mercato aperto.

Nuvalent, Inc.

One Broadway
14th Floor
Cambridge, MA 02142
United States
857 357 7000
https://www.nuvalent.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 92

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. James R. Porter Ph.D.	CEO, President & Director	1,05M	N/D	1976
Prof. Matthew D. Shair Ph.D.	Founder, Head of Scientific Advisory Board & Director	239k	N/D	1969
Dr. Christopher D. Turner M.D.	Chief Medical Officer	750,97k	N/D	1969
Dr. Benjamin Lane Ph.D.	Senior Vice President of Technical Operations	N/D	N/D	N/D
Ms. Deborah Ann Miller J.D., Ph.D.	Chief Legal Officer & Secretary	595,96k	N/D	1976
Mr. Matthew Metivier	Senior Vice President of Human Resources	N/D	N/D	N/D
Ms. Darlene Noci	Chief Development Officer	N/D	N/D	1978
Mr. Henry Pelish Ph.D.	Senior Vice President of Drug Discovery	N/D	N/D	N/D
Mr. John Soglia Ph.D.	Senior Vice President of Translational Development	N/D	N/D	N/D
Ms. Perrin Wilson B.S., Ph.D.	Senior Vice President of Business Development & Strategy	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Nuvalent, Inc. al 1 maggio 2024 è 9. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 7; diritti degli azionisti: 10; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.